Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)
ConditionCervical Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCentre Paul Strauss
About this trial
\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge.
Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.
Eligibility criteria
Qualifiers
Patients aged from 18 years old and over
Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment.
For women of childbearing potential : Adequate contraception throughout study participation.
Disqualifiers
Oncological history that could possibly interfere with imaging results interpretation, apart from cervical cancer
Extra-nodal metastasis clinically or radiologically proven before study participation
Contraindication to MRI or injection of contrast agents containing gadolinium
Contraindication to lumbo-aortic lymphadenectomy
Trial design
Treatments tested in this trial
- 18-FDG PET-MRI
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov